Suppr超能文献

病例报告:阿比特龙治疗前列腺癌脑转移

Case Report: Abiraterone in brain metastases from prostate cancer.

作者信息

Peres Tobias, Aeppli Stefanie, Fischer Stefanie, Rothermundt Christian

机构信息

Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen (KSSG), St. Gallen, Switzerland.

Department of Medical Oncology and Cancer Centre, Cantonal Hospital Lucerne (LUKS), Lucerne, Switzerland.

出版信息

Front Oncol. 2025 Apr 11;15:1555897. doi: 10.3389/fonc.2025.1555897. eCollection 2025.

Abstract

BACKGROUND

Prostate carcinoma (PC) is the most common cancer in men worldwide. However, brain metastases (BM) from prostate cancer are extremely rare events, usually in the later course of the disease. There is no established standard of care treatment for this situation. The efficacy of androgen synthesis inhibitor abiraterone in BM from PC is unknown.

CASE

We herein report the case of an 83-year-old patient with metastatic hormone-sensitive PC who had multiple BM at primary diagnosis, clinically manifesting with dizziness, ataxia, and unsteady gait. Combination of abiraterone and androgen deprivation therapy showed exceptional sustained cerebral tumor response. After 12 months of treatment, the patient is asymptomatic with an excellent performance status.

CONCLUSION

Symptomatic BM from PC is a rarity but can show sustained response to abiraterone and androgen deprivation therapy. After comprehensive literature search, there is no comparable case published to date.

摘要

背景

前列腺癌(PC)是全球男性中最常见的癌症。然而,前列腺癌脑转移(BM)极为罕见,通常发生在疾病晚期。目前尚无针对这种情况的既定标准治疗方案。雄激素合成抑制剂阿比特龙在前列腺癌脑转移中的疗效尚不清楚。

病例

我们在此报告一例83岁转移性激素敏感性前列腺癌患者,初诊时即有多处脑转移,临床表现为头晕、共济失调和步态不稳。阿比特龙与雄激素剥夺疗法联合使用显示出异常持久的脑肿瘤反应。治疗12个月后,患者无症状,身体状况良好。

结论

前列腺癌引起的有症状脑转移很罕见,但对阿比特龙和雄激素剥夺疗法可表现出持久反应。经全面文献检索,迄今为止尚无类似病例发表。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baa5/12021617/6e42d23cb0be/fonc-15-1555897-g001.jpg

相似文献

1
Case Report: Abiraterone in brain metastases from prostate cancer.
Front Oncol. 2025 Apr 11;15:1555897. doi: 10.3389/fonc.2025.1555897. eCollection 2025.
3
A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
Eur Urol Oncol. 2019 Nov;2(6):649-655. doi: 10.1016/j.euo.2019.01.004. Epub 2019 Jan 30.
6
A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high-risk prostate cancer.
IJU Case Rep. 2023 Jul 21;6(5):282-285. doi: 10.1002/iju5.12604. eCollection 2023 Sep.
10
Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
Expert Rev Anticancer Ther. 2020 Aug;20(8):629-638. doi: 10.1080/14737140.2020.1785289. Epub 2020 Jun 25.

本文引用的文献

1
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Eur Urol. 2025 Feb;87(2):157-216. doi: 10.1016/j.eururo.2024.09.017. Epub 2024 Oct 11.
2
Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)-A Potential New Standard of Care.
Curr Oncol. 2023 Apr 20;30(4):4365-4378. doi: 10.3390/curroncol30040332.
3
The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review.
Prostate Cancer. 2022 Nov 27;2022:5324600. doi: 10.1155/2022/5324600. eCollection 2022.
6
Prostate cancer.
Nat Rev Dis Primers. 2021 Feb 4;7(1):9. doi: 10.1038/s41572-020-00243-0.
7
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
8
Prostate Cancer Central Nervous System Metastasis in a Contemporary Cohort.
Clin Genitourin Cancer. 2021 Jun;19(3):217-222.e1. doi: 10.1016/j.clgc.2020.07.012. Epub 2020 Aug 22.
9
Prostate Cancer Brain Metastases: A Single-Institution Experience.
World Neurosurg. 2020 Jun;138:e445-e449. doi: 10.1016/j.wneu.2020.02.152. Epub 2020 Mar 5.
10
Three cases of brain metastasis from castration-resistant prostate cancer.
Clin Case Rep. 2019 Dec 4;8(1):96-99. doi: 10.1002/ccr3.2587. eCollection 2020 Jan.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验